Bone marrow stromal cell-mediated gene therapy for hemophilia A: In vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648

Human Gene Therapy

Volumn 10, Issue 1, 1999, Pages 61-76

  Chiang, Gisela G ^a   Rubin, Hillard L ^a   Cherington, Van ^a   Wang, Ti ^a   Sobolewski, Joyce ^a   McGrath, Claire A ^a   Gaffney, Anita ^a   Emami, Shahin ^b   Sarver, Nava ^c   Levine, Peter H ^d   Greenberger, Joel S ^a   Hurwitz, David R ^a  

^a ALG Company   (United States)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Memorial Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; PLASMID VECTOR; THROMBIN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DNA TRANSFECTION; DOG; GENE THERAPY; GENETIC TRANSDUCTION; HEMOPHILIA A; HUMAN; IMMUNOBLOTTING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; RETROVIRUS; STROMA CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOTTING, WESTERN; BONE MARROW; BONE MARROW CELLS; DOGS; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MODELS, BIOLOGICAL; PLASMIDS; PRECIPITIN TESTS; RETROVIRIDAE; STROMAL CELLS; THROMBIN; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 0032958003     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950019192     Document Type: Article

References (51)

1. ADAMSON, R. (1994). Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann. Hematol. 68, S9-S14.
2. ALEDORT, L.M., and BOHN, R.L. (1996). Prophylaxis and continuous infusion for hemophilia: Can we afford it? Blood Coagul. Fibrinol. 7(Suppl. 1), S35-S37.
3. ANDERSSON, L.O., FORSMAN, N., HUANG, K., LARSEN, K., LUNDIN, A., PAVLU, B., SANDBERG, H., SEWERIN, K., and SMART, J. (1986). Isolation and characterization of human factor VIII: Molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc. Natl. Acad. Sci. U.S.A. 83, 2979-2983.
4. BERNTORP, E. (1997). Second generation, B-domain deleted recombinant factor VIII. Thromb. Haemost. 78, 256-260.
5. BIHOREAU, N., PAOLANTONACCI, P., BARDELLE, C., FONTAINE-AUPART, M.P., KRISHNAN, S., YON, J., and ROMET-LEMONNE, J.L. (1991). Structural and functional characterization of factor VIII-delta II, a new recombinant factor VIII lacking most of the B-domain. Biochem. J. 277, 23-31.
6. BOULIKAS, T. (1996). Gene therapy to human diseases: Ex vivo and in vivo studies. Int. J. Oncol. 9, 1239-1251. [Review]
7. BRETTLER, D.B., and LEVINE, P.H. (1994). Clinical manifestations and therapy of inherited coagulation factor deficiencies. In Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd Ed. R.W. Colman, J. Hirsh, V.J. Marder, and E.W. Salzman, eds. (Lippincott, Philadelphia, PA) pp. 169-183.
8. CHERINGTON, V., CHIANG, G.G., McGRATH, C.A., GAFFNEY, A., GALANOPOULOS, T., BIZINKAUSKAS, C.B., HANSEN, M., SOBOLEWSKI, J., LEVINE, P.H., GREENBERGER, J.S., and HURWITZ, D.R. (1998). Retroviral vector modified bone marrow stromal cells secrete biologically active factor IX in vitro and deliver therapeutic levels of factor IX to the plasma of dogs following infusion. Hum. Gene Ther. 9, 1397-1407.
9. CHIANG, G.G., McGRATH, C.A., NATALE, A., GALANOPOULOS, T., CHERINGTON, V., BIZINKAUSKAS, C.B., MERRILL, W., HANSEN, M., LEVINE, P.H., GREENBERGER, J.S., and HURWITZ, D.R. (1998). Retroviral vector transduced autologous bone marrow stromal cells express human growth hormone or human factor IX into the circulation of reinfused dogs. In Hematopoietic Microenvironment. A. Keating and J.S. Greenberger, eds. (Humana Press, London) (in press).
10. CHUAH, M.K., VANDENDRIESSCHE, T., and MORGAN, R.A. (1995). Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum. Gene Ther. 6, 1363-1377.
11. CHUAH, M.K., BREMS, H., VANSLEMBROUCK, V., COLLEN, D., and VANDENDRIESSCHE, T., (1998). Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum. Gene Ther. 9, 353-365.
12. CONNELLY, S., and KALEKO, M. (1997). Gene therapy for hemophilia A. Thromb. Haemost. 78, 31-36.
13. COONROD, A., LI, F.-Q., and HORWITZ, M. (1997). On the mechanism of DNA transfection: Efficient gene transfer without viruses. Gene Ther. 4, 1313-1321.
14. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
15. DWARKI, V.J., BELLONI, P., NIJJAR, T., SMITH, J., COUTO, L., RABIER, M., CLIFT, S., BERNS, A., and COHEN, L.K. (1995). Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. U.S.A. 92, 1023-1027.
16. EATON, D., RODRIGUEZ, H., and VEHAR, G.A. (1986a). Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25, 505-512.
17. EATON, D.L., WOOD, W.I., EATON, D., HASS, P.E., HOLLINGSHEAD, P., WION, K., MATHER, J., LAWN, R.M., VEHAR, G.A., and GORMAN, G. (1986b). Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 25, 8343-8347.
18. EMAMI, S., MERRILL, W., CHERINGTON, V., CHIANG, G.G., KIRCHGESSER, M., APPEL, J.M., HANSEN, M., LEVINE, P.H., GREENBERGER, J.S., and HURWITZ, D.R. (1997). Enhanced growth of canine bone marrow stromal cell cultures in the presence of acidic fibroblast growth factor and heparin. In Vitro Cell Dev. Biol. Anim. 33, 503-511.
19. FALLAUX, F.J., HOEBEN, R.C., and BRIET, E. (1995). State and prospects of gene therapy for the hemophilias. Thromb. Haemost. 74, 266-273.
20. GREENBERGER, J.S. (1996). Methods for the use of stromal cells for therapeutic gene therapy. In Methods in Molecular Medicine, Gene Therapy Protocols. P. Robbins, ed. (Humana Press, Totowa, NJ) pp. 375-390.
21. GRÜNERT, S., and JACKSON, R.J. (1994). The immediate downstream codon strongly influences the efficiency of utilization of eukaryotic translation initiation codons. EMBO J. 13, 3618-3630.
22. GUINN, B., WANG, X.-H., LARAYA, P., and KEATING, A. (1996). Xenotransplantation of electrotransfected marrow stromal cells express human factor IX protein in SCID mice: A pre-clinical model for gene therapy. Blood 88(10: Suppl. 1), 3921.
23. HOEBEN, R.C., VAN DER JAGT, R.C., SCHOUTE, F., VAN TILBURG, N.H., VERBEET, M.P., BRIET, E., VAN ORMONDT, H., and VAN DER EB, A.J. (1990). Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J. Biol. Chem. 265, 7318-7323.
24. HOYER, L.W. (1995). Why do so many haemophilia A patients develop an inhibitor? Br. J. Haematol. 90, 498-501.
25. HURWITZ, D.R., KIRCHGESSER, M., MERRILL, W., GALANOPOULOS, T., McGRATH, C.A., EMAMI, S., HANSEN, M., CHERINGTON, V., APPEL, J.M., BIZINKAUSKAS, C.B., BRACKMANN, H.H., LEVINE, P.H., and GREENBERGER, J.S. (1997). Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum. Gene Ther. 8, 137-156.
26. HUSS, R., SMITH, P.O., MYERSON, D.H., and DEEG, H.J. (1995). Homing and immunogenicity of murine stromal cells transfected with xenogeneic MHC class II genes. Cell Transplant. 4, 483-491.
27. ISRAEL, D.I., and KAUFMAN, R.J. (1990). Retroviral-mediated transfer and amplification of a functional human factor VIII gene. Blood 75, 1074-1080.
28. KAUFMAN, R.J. (1992). Biological regulation of factor VIII activity. Annu. Rev. Med. 43, 325-339.
29. KAUFMAN, R.J., WASLEY, L.C., and DORNER, A.J. (1988). Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 263, 6352-6362.
30. KOZAK, M. (1989). The scanning model for translation: An update. J. Cell Biol. 108, 229-241.
31. KRALL, W.J., SKELTON, D.C., YU, X.J., RIVIERE, I., LEHN, P., MULLIGAN, R.C., and KOHN, D.B. (1996). Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther. 3, 37-48.
32. LABAT-MOLEUR, F., STEFFAN, A.M., BRISSON, C., PERRON, H., FEUGEAS, O., FURSTENBERGER, P., OBERLING, F., BRAMBILLA, E., and BEHR, J.P. (1996). An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther. 3, 1010-1017.
33. LIND, P., LARSSON, K., SPIRA, J., SYDOW-BACKMAN, M., ALMSTEDT, A., GRAY, E., and SANDBERG, H. (1995). Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur. J. Biochem. 232, 19-27.
34. LYNCH, C.M., ISRAEL, D.I., KAUFMAN, R.J., and MILLER, A.D. (1993). Sequences in the coding region of cloning factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum. Gene Ther. 4, 259-272.
35. MARKOWITZ, D., GOFF, S., and BANK, A. (1988a). A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol. 62, 1120-1124.
36. MARKOWITZ, D., GOFF, S., and BANK, A. (1988b). Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400-406.
37. MEULIEN, P., FAURE, T., MISCHLER, F., HARRER, H., ULRICH, P., BOUDERBALA, B., DOTT, K., SAINTE MARIE, M., MAZURIER, C., WIESEL, M.L., VAN DE POL, H., CAZENAVE, J.-P., and PAVIRINI, A. (1988). A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Protein Eng. 2, 301-306.
38. NOLTA, J.A., HANLEY, M.B., and KOHN, D.B. (1994). Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: Analysis of gene transduction of long-lived progenitors. Blood 83, 3041-3051.
39. PAVIRANI, A., MEULIN, P., HARRER, H., SCHAMBER, F., DOTT, K., VILLEVAL, D., CORDIER, Y., WIESEL, M., MAZURIER, C., VAN DE POL, H., PIQUET, Y., CAZENAVE, J., and LECOCQ, P. (1987). Choosing a host cell for active recombinant factor VIII production using vaccinia virus. Bio/Technology 5, 987-990.
40. PEREIRA, R.F., HALFORD, K.W., O'HARA, M.D., LEEPER, D.B., SOKOLOV, B.P., POLLARD, M.D., BAGASRA, O., and PROCKOP, D.J. (1995). Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc. Natl. Acad. Sci. U.S.A. 92, 4857-4861.
41. PITTMAN, D.D., and KAUFMAN, R.J. (1988). Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc. Natl. Acad. Sci. U.S.A. 85, 2429-2433.
42. PITTMAN, D.D., ALDERMAN, E.M., TOMKINSON, K.N., WANG, J.H., GILES, A.R., and KAUFMAN, R.J. (1993). Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81, 2925-2935.
43. PROCKOP, D.J. (1997). Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 276, 71-74.
44. ROSENDAAL, F.R., SMIT, C., and BRIET, E. (1991). Hemophilia treatment in historical perspective: A review of medical and social developments. Ann. Hematol. 62, 5-15.
45. SARVER, N., RICCA, G.A., LINK, J., NATHAN, M.H., NEWMAN, J., and DROHAN, W.N. (1987). Stable expression of recombinant factor VIII molecules using a bovine papillomavirus vector. DNA 6, 553-564.
46. THOMPSON, A.R. (1995). Progress towards gene therapy for the hemophilias. Thromb. Haemost. 74, 45-51.
47. TOOLE, J.J., KNOPF, J.L., WOZNEY, J.M., SULTZMAN, L.A., BUECKER, J.L., PITTMAN, D.D., KAUFMAN, R.J., BROWN, E., SHOEMAKER, C., ORR, E.C., AMPHLETT, G.W., FOSTER, W.B., COE, M.L., KNUTSON, G.J., FASS, D.N., and HEWICK, R.M. (1984). Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature (London) 312, 342-347.
48. TOOLE, J.J., PITTMAN, D.D., ORR, E.C., MURTHA, P., WASLEY, L.C., and KAUFMAN, R.J. (1986). A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U.S.A. 83, 5939-5942.
49. VEHAR, G.A., KEYT, B., EATON, D., RODRIGUEZ, H., O'BRIEN, D.P., ROTBLAT, F., OPPERMANN, H., KECK, R., WOOD, W.I., HARKINS, R.N., TUDDENHAM, E.G.D., LAWN, R.M., and CAPON, D.J. (1984). Structure of human factor VIII. Nature (London) 312, 337-342.
50. VLOT, A.J., KOPPELMAN, S.J., BOUMA, B.N., and SIXMA, J.J. (1998). Factor VIII and von Willebrand factor. Thromb. Haemost. 79, 456-465.
51. WALTER, J., and HIGH, K.A. (1997). Gene therapy for the hemophilias. Adv. Vet. Med. 40, 119-134.